Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

338 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency and anemia in pregnancy and neonates, and that it mediates the feedback mechanism to correct iron deficiency and anemia. To address this research gap, the investigators will measure ERFE in maternal serum, umbilical cord serum and placental tissue using an existing biospecimen archive.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Erythropoietin in Newborns and Children

NCT03957863

Newborn Infant Child Under One Year of Age

UNKNOWN

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514

Infant, Newborn Infant, Low Birth Weight Infant, Small for Gestational Age +2 more

COMPLETED PHASE2/PHASE3

Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

NCT00945789

Hypoxic Ischemic Encephalopathy

COMPLETED PHASE1/PHASE2

Iron Metabolism in Small Pre Term Newborns

NCT01443195

Preterm Iron Metabolism Iron Overload

UNKNOWN NA

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240

Congenital Heart Disease Hypoplastic Left Heart Syndrome Transposition of the Great Arteries +1 more

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Anemia Newborn; Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant Adolescents

No interventions assigned to this group

Pregnant Women Carrying Multiple Fetuses

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy pregnant volunteers

Exclusion Criteria

* Hemoglobinopathies
* Pre-existing diabetes
* Malabsorption diseases
* Pregnancy induced hypertension
* Elevated diastolic blood pressure (\>110)
* Previous treatment for lead exposure or elevated childhood lead concentrations.
* Preexisting medical conditions known to impact iron homeostasis

Minimum Eligible Age

11 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes